Survival
Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning
Frontiers in Endocrinology 2022 November 29 [Link] Yingqi Xiao, Wei Huang, Li Zhang, Hongwei Wang Abstract Background: Glycolysis-related genes as prognostic markers in malignant pleural mesothelioma (MPM) is still unclear. We hope to explore the relationship between glycolytic pathway genes and MPM prognosis by constructing prognostic risk models through bioinformatics and machine learning. Methods: The…
Read MoreMultimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MorePotential Roles of Exosomes in the Development and Detection of Malignant Mesothelioma: An Update
International Journal of Molecular Sciences 2022 December 6 [Link] Phillip Munson, Arti Shukla Abstract Malignant mesothelioma (MM) is a devastating cancer of mesothelial cells, caused by asbestos exposure. Limited knowledge regarding the detection of asbestos exposure and the early diagnosis of MM, as well as a lack of successful treatment options for this deadly cancer,…
Read MoreThe STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
Frontiers in Immunology 2022 November 18 [Link] Peter T Graham, Anna K Nowak, Scott M J Cornwall, Irma Larma, Delia J Nelson Abstract We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a neo tumor antigen. Dose response experiments alongside testing…
Read MoreA Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Clinical Cancer Research 2022 December 5 [Link] Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y Wang, Daniela Ramos, Jong Min Choi, Taylor Splawn, Monica Espinoza, Michelle Almarez, Leandria Hosey, Eunji Jo, Susan G Hilsenbeck, Christopher I Amos, R Taylor Ripley, Bryan M Burt Abstract Purpose: We report the results of a phase 2, randomized, window-of-opportunity…
Read MoreFinal results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
ESMO Open 2022 December [Link] S Canova, G L Ceresoli, F Grosso, P A Zucali, F Gelsomino, G Pasello, M Mencoboni, E Rulli, F Galli, I De Simone, L Carlucci, A De Angelis, M Belletti, M Bonomi, A D’Aveni, M Perrino, F Bono, D L Cortinovis Abstract Background: Malignant pleural mesothelioma (MPM) is a cancer…
Read MoreUsefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study
Lung Cancer 2022 November 19 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima Abstract Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP)…
Read MoreIsolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
Cancers 2022 November 16 [Link] Hatice Ulku Osmanbeyoglu, Drake Palmer, April Sagan, Eleonora Sementino, Michael J Becich, Joseph R Testa Abstract Malignant pleural mesothelioma (MPM), an aggressive cancer of the mesothelial cells lining the pleural cavity, lacks effective treatments. Multiple somatic mutations and copy number losses in tumor suppressor genes (TSGs) BAP1, CDKN2A/B, and NF2…
Read MoreThe Effects of Preserving the Diaphragm on Early and Late Outcome of Lung-Sparing Radical Surgery for Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2022 November 19 [Link] Michelle Lee, Luigi Ventura, Ralitsa Baranowski, Joanne Hargrave, David Waller Abstract Background: The accepted aim of radical surgery for malignant pleural mesothelioma (MPM) is the achievement of macroscopic complete resection (MCR) whilst reducing perioperative morbidity by preserving normal tissue. Whilst preservation of the lung by pleurectomy/decortication (PD)…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read More